MarginsXMarginsX
Home › Markets › Health Care › PRME

Prime Medicine Inc. (PRME)

PRME trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.19
-1.87% on the day
Market cap
$762.3M
Small cap
Revenue · 2025
$4.6M
+55.3% on 2024
Net income · 2025
-$201.1M
-4342.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/0001628280-26-013569-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPRME on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2022
SEC CIK0001894562
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$4.6M
Net income-$201.1M
Operating income-$208.3M
Net margin-4342.4%
Operating margin-4498.1%
Revenue growth+55.3%
Cash$63.0M
Total assets$342.7M
P/E (computed)Net income was not positive
P/S (computed)164.6×

Warning signs

Cash runway
4.2 months
$54.9M cash at September 30, 2026
Share count, 1 year
+0.8%
2025-10-31 to 2026-10-31 · +86.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued."
10-Q 2026-11-12
Cash and burn$54.9M cash; operating cash flow -$39.4M a quarter.Report 2026-09-30
Shares outstanding181,921,405 (2026-10-31); 180,510,658 a year earlier; 97,324,301 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-11-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$4.2M-$39.0M-$36.7M$54.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$42.1M-$41.0M$47.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$49.1M-$42.7M$64.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
$838K-$46.1M-$37.3M$63.0MNo debt tags$4.6M10-K 2026-03-03
Q3 2025
2025-09-30
$1.2M-$50.6M-$35.0M$71.4MNo debt tags$6.0M10-Q 2026-11-12
Q2 2025
2025-06-30
$1.1M-$52.6M-$41.4M$53.8MNo debt tags$5.0M10-Q 2025-08-07
Q1 2025
2025-03-31
$1.5M-$51.9M-$48.9M$91.9MNo debt tags$3.8M10-Q 2025-05-08
Q4 2024
2024-12-31
$2.2M-$42.3M$16.2M$182.5MNo debt tags$3.0M10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-12
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 306 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.2%
1 month+28.6%
3 months+34.7%
Year to date+23.1%
1 year+28.2%
From 52-week high-20.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
AURAAura Biosciences Inc.$7.22+1.55%$751.4M
GLUEMonte Rosa Therapeutics Inc.$9.16-2.24%$782.7M
SLDBSolid Biosciences Inc.$6.48-5.26%$723.2M
MGTXMeiraGTx Holdings plc$8.74-4.79%$854.2M
ATTOAttovia Therapeutics Inc.$14.72-2.68%$673.1M
DBVTDBV Technologies S.A.$10.27-6.76%$645.8M
BBTXBambusa Therapeutics Inc.$15.98-0.68%$645.4M
FDMT4D Molecular Therapeutics Inc.$11.29-7.69%$636.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier